News & Publications

Financing co-led by Anthos Capital and SALT Fund; Anthos’s Paul Farr and biotech leader Brent Saunders to join Board of Directors.

Cambrian Biopharma Chief Operating Officer, Juliette Han, PhD named as one of the Top 25 Women Leaders in Biotechnology by The Healthcare Technology Report.

Does anyone really want to live until 180? Progress in longevity science is abundant at the moment, from healthspan hacking to novel therapies being brought under development. Our panel of experts discuss the philosophical and scientific innovations taking place at the cutting edge of the life-extensionists field and what implications they could have for us all.

The Foresight Institute is a non-profit organization that was founded in 1986 on a vision of coming revolutions in technology that will bring extraordinary opportunities, as well as unprecedented challenges. Cambrian Biopharma CEO James Peyer led this webinar for their Biotech & Health Extension series, focused on strategies for finding and building geroperotective drugs.

James Peyer to present new research in the biology of aging at the world's largest aging research for drug discovery conference.

An exclusive Q&A with Cambrian Biopharma’s CEO, James Peyer – a discussion of the Hallmarks of Aging and classifying aging as a disease.

Cambrian Biopharma, a distributed development company, exits stealth mode with the announcement that it has raised $60 million in private financing to develop medicines to extend healthy lifespan.

An exclusive Q&A with Cambrian Biopharma’s Chief Operating Officer, Juliette Han.

In 2015, The UN declared February 11th the “International Day of Women and Girls in Science." Today marks the sixth celebration of the vital role women and girls play in science, technology and innovation. We are delighted to showcase some of the women whose work we have covered or will be covering and to play our part in promoting women and girls in science.

Cambrian Biopharma is one of the newly emerging distributed drug discovery companies that applies a new twist to investing in interesting science. PM360 spoke with co-founder James Peyer about this new model, why he decided to focus on the biology of aging, and more.

"Rational Mind", a science series hosted by engineer and influencer Pietro Boselli, aims to inspire viewers to use rationality and critical thinking to approach complex issues. In this episode, James discusses the longevity science space and the opportunities and challenges ahead.

James Peyer is the Co-Founder and CEO of Cambrian Biopharma, a Distributed Development Company developing therapeutics targeting the biology of aging. Cambrian builds, finances, and manages a pipeline of therapeutics. In this conversation, we discuss molecular damage, adding healthy years to your life, prevention vs reversal of diseases, and distributed drug companies.

Cambrian Biopharma, a new type of biotech venture raising $60 million to execute on a model known as the “Distributed Development Company” or “DisCo,” that is, a multi-asset company combining the advantages of the standard biotech firm with those of a venture capital fund and biotech incubator, to establish a platform for the development of new anti-aging therapeutics.

A study on John Cunningham virus-like particles (JC VLPs) and their potential use in developing a delivery system for transport of genes and small molecule cargoes across the blood-brain barrier (BBB).

A review of recent developments and challenges related to selected blood–brain barrier-crossing strategies — with a focus on non- invasive approaches such as receptor-mediated transcytosis and the use of neurotropic viruses, nanoparticles and exosomes — and analysis of their potential in the treatment of CNS disorders.